Lancet HIV

Papers
(The H4-Index of Lancet HIV is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Transplant donation without discrimination234
How do we prevent anal cancer in people living with HIV?205
Argentina updates HIV laws138
Evidence supports use of on-demand PrEP for HIV prevention136
How much could long-acting PrEP cost in South Africa?133
The Australian AIDS crisis through the eyes of volunteers132
Correction to Lancet HIV 2022; 9: e791–800132
HIV and COVID-19: juxtaposition of two pandemics130
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia 103
Optimising anal cancer screening through risk stratification99
Lung cancer in people living with HIV96
Controversial chronicler of LGBTQ rights95
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial95
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?85
Steps toward quick and equitable roll-out of lenacapavir83
Are we ready for long-acting HIV treatment for adolescents?81
Risk estimation in HIV reveals our usual blind spots81
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c76
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma74
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial71
Lenacapavir: an attractive option, but proceed with caution70
All roads lead to Westminster: the infected blood scandal69
Redefining care: injectable HIV treatment for adolescents69
Unheard testimony63
Gains and gaps: addressing HIV in diverse sex worker groups61
Fate of people with HIV in jeopardy in Ukraine58
Stigma reduction is key to improving the HIV care continuum55
Game-changing study of second-line HIV treatment52
Integration of sexual health and HIV services51
Reducing HIV transmission in British Columbia, Canada51
Recent gay Black history in the UK50
Suicide prevention research is crucial to achieving health equity for people with HIV49
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther46
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis46
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl43
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries43
Equitable access to long-acting PrEP on the way?43
More evidence for worse COVID-19 outcomes in people with HIV42
Sex as a biological variable in HIV-1 and schistosome co-infection42
Making America unhealthy again41
A public health approach to drug use crucial to ending AIDS40
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial40
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study40
0.032139778137207